Panbela Therapeutics (NASDAQ:PBLA) Trading 7.3% Higher

Panbela Therapeutics, Inc. (NASDAQ:PBLA)’s share price shot up 7.3% during mid-day trading on Thursday . The company traded as high as $0.48 and last traded at $0.44. 25,779 shares changed hands during trading, a decline of 96% from the average session volume of 573,537 shares. The stock had previously closed at $0.41.

Analyst Upgrades and Downgrades

Separately, Roth Mkm reaffirmed a “buy” rating on shares of Panbela Therapeutics in a research note on Wednesday, March 27th.

Panbela Therapeutics Stock Up 7.3 %

The firm has a fifty day moving average price of $0.75 and a two-hundred day moving average price of $8.06. The stock has a market capitalization of $1.53 million, a P/E ratio of 0.00 and a beta of 1.48.

Panbela Therapeutics (NASDAQ:PBLA) last released its quarterly earnings data on Tuesday, March 26th. The company reported ($65.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($24.34) by ($41.56). Sell-side analysts anticipate that Panbela Therapeutics, Inc. will post -5.25 earnings per share for the current fiscal year.

About Panbela Therapeutics

Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase.